Targeting TREM-1 to restore immune balance
Inotrem is a French clinical-stage biopharmaceutical company founded in 2013 specializing in immunotherapy for acute and chronic inflammatory syndromes, including sepsis. The company has developed a TREM-1 inhibition platform and lead compound nangibotide, and maintains offices in Paris and a technology center in Nancy, France.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2021
Jul 2021
Feb 2020
Sep 2019
Mar 2014
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
